WNK1 promotes head and neck squamous cell carcinoma progression through activation of NF-κB signaling pathway
Guardat en:
| Publicat a: | Discover Oncology vol. 16, no. 1 (Dec 2025), p. 1822 |
|---|---|
| Autor principal: | |
| Altres autors: | , , , , , , , , , , |
| Publicat: |
Springer Nature B.V.
|
| Matèries: | |
| Accés en línia: | Citation/Abstract Full Text Full Text - PDF |
| Etiquetes: |
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|
MARC
| LEADER | 00000nab a2200000uu 4500 | ||
|---|---|---|---|
| 001 | 3257698744 | ||
| 003 | UK-CbPIL | ||
| 022 | |a 2730-6011 | ||
| 022 | |a 1868-8497 | ||
| 022 | |a 1868-8500 | ||
| 024 | 7 | |a 10.1007/s12672-025-03637-2 |2 doi | |
| 035 | |a 3257698744 | ||
| 045 | 2 | |b d20251201 |b d20251231 | |
| 100 | 1 | |a Chen, Ru-zhen |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 245 | 1 | |a WNK1 promotes head and neck squamous cell carcinoma progression through activation of NF-κB signaling pathway | |
| 260 | |b Springer Nature B.V. |c Dec 2025 | ||
| 513 | |a Journal Article | ||
| 520 | 3 | |a BackgroundRecurrence and metastasis represent the primary causes of therapeutic failure in head and neck squamous cell carcinoma (HNSCC). However, the underlying molecular mechanisms driving these processes remain incompletely elucidated.MethodsWNK1 (with-no-lysine kinase 1) expression in both normal and HNSCC tissues was analyzed using the TCGA, TIMER2.0 and Clinical Proteomic Tumor Analysis Consortium (CPTAC) datasets, and further validated in HNSCC cell lines by Western blot. Cell Counting Kit-8 (CCK-8), colony formation, Transwell, and orthotopic xenograft assays were conducted to assess the biological role of WNK1 in HNSCC proliferation and metastasis. Liquid chromatography-tandem mass spectrometry (LC-MS/MS) -based quantitative proteomics and post-translational modification profiling were performed to explore the underlying molecular mechanisms.ResultsWNK1 overexpression was significantly elevated in HNSCC tissues and cell lines and was correlated with reduced overall survival. WNK1 knockdown suppressed tumor growth and metastasis both in vivo and in vitro. Proteomic and phosphoproteomic profiling of WNK1-driven alterations identified critical signaling pathways closely associated with tumor malignancy. Specifically, WNK1 promotes NF-κB activation through RELA (p65) phosphorylation and nuclear accumulation, resulting in the upregulation of pro-tumorigenic effectors.ConclusionsElevated WNK1 drives invasive progression and distant metastasis in HNSCC through NF-κB-dependent transcriptional reprogramming, highlighting its potential as a novel therapeutic target for HNSCC. | |
| 610 | 4 | |a Food & Drug Administration--FDA | |
| 653 | |a Cancer | ||
| 653 | |a Medical prognosis | ||
| 653 | |a Metastasis | ||
| 653 | |a Squamous cell carcinoma | ||
| 653 | |a Genomes | ||
| 653 | |a Phosphorylation | ||
| 653 | |a Tumors | ||
| 653 | |a Genes | ||
| 653 | |a Human papillomavirus | ||
| 653 | |a Cell growth | ||
| 653 | |a Kinases | ||
| 653 | |a Protein expression | ||
| 653 | |a Comparative analysis | ||
| 653 | |a Proteins | ||
| 700 | 1 | |a Li, Rui |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Cheng, Bing-lin |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Lu, Si-bei |u Southern Medical University, The First School of Clinical Medicine, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Hu, Wen |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Lin, Feng |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Wen, Xin |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Chen, Yue |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Wang, Ying-lei |u Southern Medical University, The First School of Clinical Medicine, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Zhang, Mo-ting |u Southern Medical University, The First School of Clinical Medicine, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Hong, Xiao-hong |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 700 | 1 | |a Tang, Xin-ran |u Southern Medical University, Department of Radiation Oncology, Nanfang Hospital, Guangzhou, China (GRID:grid.284723.8) (ISNI:0000 0000 8877 7471) | |
| 773 | 0 | |t Discover Oncology |g vol. 16, no. 1 (Dec 2025), p. 1822 | |
| 786 | 0 | |d ProQuest |t Health & Medical Collection | |
| 856 | 4 | 1 | |3 Citation/Abstract |u https://www.proquest.com/docview/3257698744/abstract/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text |u https://www.proquest.com/docview/3257698744/fulltext/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |
| 856 | 4 | 0 | |3 Full Text - PDF |u https://www.proquest.com/docview/3257698744/fulltextPDF/embedded/J7RWLIQ9I3C9JK51?source=fedsrch |